Skip to main content
Signal8

BioLineRx Ltd. (BLRX)

Sector: Pharmaceutical Preparations

Industry: Biotechnology

BioLineRx Ltd. logo

BioLineRx Ltd.

NASDAQ:BLRXHealthcare
-2.61%$1.12
CLOSED
AH$1.12+0.00%vs close
Mkt Cap$5.58M
EV-
Float4.8M
O/S4.98M
VOL33K sh
$ Vol$40K
RVOL2.98×
Inst Own11.4%
SI2.8%
Net Cash/Sh-
Dilution
BioLineRx Ltd. logoNASDAQ:BLRXClosed$1.12-2.61%
Historical Data
DateOpenHighLowCloseVolume
Nov 17, 20261.191.291.111.1233,181
Nov 16, 20261.251.371.141.1516,582
Nov 13, 20261.371.541.301.3014,107
Nov 12, 20261.561.601.351.3511,472
Nov 11, 20261.551.631.481.496,363
Nov 10, 20261.701.751.451.527,684
Nov 9, 20261.641.711.581.5828,268
Nov 6, 20261.721.751.711.718,483
Nov 5, 20261.921.921.701.7715,158
Nov 4, 20261.811.921.811.868,883
Nov 3, 20261.941.991.901.9113,373
Nov 2, 20261.941.961.941.964,705
Oct 30, 20261.951.991.941.998,792
Oct 29, 20262.012.021.942.024,149
Oct 28, 20261.942.041.942.004,036
Oct 27, 20261.972.031.962.034,992
Oct 26, 20262.152.151.982.018,044
Oct 23, 20262.042.112.042.041,704
Oct 22, 20262.072.171.992.065,196
Oct 21, 20262.192.191.962.111,856
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
7
HOLD
0
SELL
0
TOTAL7
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
11.4%
Institutional
(17)
-
Insiderⓘ
(3)
0.0%
5%+ Owners
(0)
-
Unattributed (incl. retail)ⓘ
Institutional11.4%
Sources: 13F, Form 4, 13D/13GO/S: 5.0M · as of 24 Sep 2026 · SEC filings
Insiders & Institutional Holders
About

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology.

The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.

The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Key Metrics
Market Cap$5.58M
Enterprise Value--
P/E Ratio-0.39
Est. Net Cash/Share--
Institutional Ownership11.40%

based on 4.98M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryILIL
IPO DateJul 27, 2011
Shares Outstanding4.98M
Authorized Shares
Float4.80M
52-Week Range
$1.11$3.95
$1.12(0th percentile)
Volume
Average Daily Volume11.13K
33.18K today vs 11.13K avg(+198%)

30d Avg

11.13K

60d Avg

13.87K

90d Avg

18.15K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

Signal8's dilution snapshot of BLRX as of Dec 31, 2025 records an effective F-3 shelf registration (effective Jan 5, 2024), 10 outstanding warrant series and a registered direct offering closed Aug 31, 2026, from SEC filings. BioLineRx Ltd. (NASDAQ: BLRX) traded at $1.12 on Nov 17, 2026, down 2.61% from the previous close of $1.15. 52-week range: $1.11 to $3.95. The company is in the Healthcare sector (Biotechnology).